We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




"Metal Detector" Algorithm Hunts Down Vulnerable Tumors

By LabMedica International staff writers
Posted on 15 Apr 2025

Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. More...

This breakthrough could eventually be used to pinpoint cancer patients most likely to benefit from immunotherapy.

The algorithm, named PRRDetect, was created by researchers funded by Cancer Research UK and the NIHR at the University of Cambridge (Cambridge, UK). It works by recognizing specific patterns of mutations that emerge in cancer cells when they cannot repair DNA errors. PRRDetect represents a major leap in utilizing genomics – the study of all genetic information in a person’s DNA – to gain deeper insights into cancer. Until now, genomic sequencing (DNA reading) tests have typically focused on identifying particular mutations that drive cancer, such as those in BRCA genes, which doctors can target with specific drugs. However, this new algorithm goes beyond identifying isolated mutations by detecting broader mutation patterns, or ‘mutational signatures,’ that reveal deeper information about the cancer’s genetic makeup.

In this study, researchers focused on analyzing patterns in DNA that undergo indel mutations, a type of mutation where nucleotides (the basic units of DNA) are either inserted or deleted incorrectly in the DNA sequence. By examining nearly 5,000 tumors, the researchers identified unique mutation patterns indicative of ‘post replicative repair dysfunction’ (PRRd), a condition in which cells have faulty repair mechanisms. This data was then used to develop PRRDetect, a tool that scans genome sequences for PRRd-related mutations. Since tumors with PRRd are more responsive to immunotherapy, which activates the body's immune system to target cancer cells, the research team believes this tool could help translate genomic findings into more effective treatments for patients.

The study explored genomic data from a range of cancer types, including lung and brain tumors, as well as bowel, endometrial, skin, bladder, and stomach cancers. While there was existing evidence that PRRd was more prevalent in these cancers, PRRDetect may be the first effective tool to identify it. The research team is now working on clinical trials to evaluate how well PRRDetect can predict a patient's response to immunotherapy. Additionally, they plan to expand their genomic analysis to cover 20 cancer types, potentially leading to even more groundbreaking discoveries. Published in the journal Nature Genetics, the study also revealed new insights into the potential causes of cancer. Ten of the indel mutation patterns were linked to known carcinogens, such as tobacco use and UV light exposure, while 19 others were previously unidentified. These novel patterns could suggest unknown causes of cancer or growth mechanisms that could be targeted by new treatments.

“Cancers with faulty DNA repair are more likely to be treated successfully,” said Professor Serena Nik-Zainal, who led the first study into the new algorithm. “PRRDetect helps us better identify those cancers and, as we sequence more and more cancers routinely in the clinic, it could ultimately help doctors better tailor treatments to individual patients.”


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Mini Vortex Mixer
Vornado
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.